Pulmonary Arterial Hypertension
Q&A: Asporin linked to ‘more favorable disease profile’ in patients with PAH
Asporin has been discovered as a potential new target that may be used when developing therapeutic interventions for pulmonary arterial hypertension, according to a University of California, Los Angeles (UCLA) press release.
‘Treat what is treatable’: Organ specific approach key for systemic sclerosis management
SAN DIEGO — Clinicians managing systemic sclerosis should focus on treating “what is treatable” in each organ that is involved, according to data presented at the 2024 Congress of Clinical Rheumatology West.
All patients with systemic sclerosis require screening for interstitial lung disease, PAH
SAN DIEGO — All patients with systemic sclerosis should be screened for pulmonary arterial hypertension and interstitial lung disease, according to a speaker at the 2024 Congress of Clinical Rheumatology West.
96% of patients with PAH prefer a single-tablet combination therapy
When presented with four unlabeled treatment profiles showing five treatment attributes, 96% of patients with pulmonary arterial hypertension chose a single-tablet vs. a multi-tablet combination therapy, according to a poster.
Q&A: Yutrepia for PAH, pulmonary hypertension-ILD receives tentative FDA approval
Around 7 months after not meeting the Prescription Drug User Fee Act goal date for Yutrepia, the FDA has tentatively approved the drug for pulmonary arterial hypertension and pulmonary hypertension-associated interstitial lung disease.
Clinicians agree on individualized dosing, titration of selexipag in PAH
Health care professionals treating patients with pulmonary arterial hypertension recommend individualized dosing and titration of oral selexipag, according to a poster presented at the International Pulmonary Hypertension Conference.
FDA grants orphan drug designation to PAH treatment
The FDA granted orphan drug designation to ZMA001 as a treatment for patients with pulmonary arterial hypertension, according to a press release from Zymedi.
Internal organ involvement ‘much more’ common in late-onset systemic sclerosis
Internal organ, heart and kidney involvement, as well as pulmonary arterial hypertension, are “much more” common in cases of systemic sclerosis that develop after age 60 years, according to data published in Clinical Rheumatology.
Inhaled seralutinib reduces vascular resistance in patients with PAH over 72 weeks
SAN DIEGO — Among patients with pulmonary arterial hypertension, seralutinib lowered pulmonary vascular resistance over 72 weeks, according to research presented at the American Thoracic Society International Conference.
Combination macitentan, tadalafil tablet improves exercise capacity in PAH
SAN DIEGO — Exercise capacity improved among adults with pulmonary arterial hypertension taking a macitentan-tadalafil tablet over 68 weeks, according to research presented at the American Thoracic Society International Conference.